Top-Rated StocksTop-RatedNASDAQ:RLAY Relay Therapeutics (RLAY) Stock Price, News & Analysis $13.53 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$13.42 -0.11 (-0.81%) As of 05/22/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Relay Therapeutics Stock (NASDAQ:RLAY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Relay Therapeutics alerts:Sign Up Key Stats Today's Range$13.40▼$13.9550-Day Range$9.35▼$16.8052-Week Range$2.75▼$17.32Volume5.36 million shsAverage Volume4.36 million shsMarket Capitalization$2.59 billionP/E RatioN/ADividend YieldN/APrice Target$22.60Consensus RatingBuy Company Overview Relay Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins. The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening. This approach enables Relay to explore conformational changes in proteins that have historically been difficult to target, opening new avenues for therapeutic intervention. Relay’s pipeline comprises multiple preclinical and clinical programs aimed at oncogenic drivers implicated in a range of solid tumors. Relay Therapeutics has progressed a number of assets into human trials, with initial studies evaluating safety, tolerability and preliminary signs of clinical activity. In addition to its internal development programs, the company collaborates with academic institutions and other biopharmaceutical companies to expand the application of its platform across diverse therapeutic areas. Relay’s research efforts are supported by partnerships that bring complementary expertise and resources to accelerate the identification of novel drug candidates. Under the leadership of President and Chief Executive Officer Michael Gilman, Ph.D., Relay Therapeutics continues to advance its vision of precision oncology medicines that address unmet medical needs. The company’s operations are primarily based in the United States, while its clinical trials enroll patients across North America and select international sites. Relay Therapeutics is publicly traded on the Nasdaq under the ticker symbol RLAY.AI Generated. May Contain Errors. Read More Relay Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreRLAY MarketRank™: Relay Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 318th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingRelay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialRelay Therapeutics has a consensus price target of $22.60, representing about 67.0% upside from its current price of $13.53.Amount of Analyst CoverageRelay Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Relay Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Relay Therapeutics are expected to decrease in the coming year, from ($1.59) to ($1.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relay Therapeutics is -8.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relay Therapeutics is -8.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelay Therapeutics has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Relay Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.07% of the float of Relay Therapeutics has been sold short.Short Interest Ratio / Days to CoverRelay Therapeutics has a short interest ratio ("days to cover") of 8.72.Change versus previous monthShort interest in Relay Therapeutics has recently increased by 1.53%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRelay Therapeutics does not currently pay a dividend.Dividend GrowthRelay Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.56 News SentimentRelay Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Relay Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for RLAY on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows11 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $532,889.00 in company stock.Percentage Held by Insiders5.04% of the stock of Relay Therapeutics is held by insiders.Percentage Held by Institutions96.98% of the stock of Relay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relay Therapeutics' insider trading history. Receive RLAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RLAY Stock News HeadlinesRelay Therapeutics, Inc. (RLAY) Presents at ISSVA World Congress 2026: The Latest in Vascular Anomalies - SlideshowMay 22 at 7:25 PM | seekingalpha.comRelay Therapeutics (RLAY) Is Up 6.9% After Follow-On Offering And Early Zovegalisib Data ReleaseMay 22 at 9:40 AM | finance.yahoo.comNobody Understands Why Trump Is Invading Iran (here’s the answer)Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decision. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there is a hidden reason behind the bombing - and knowing it could change how you position your money right now.May 25 at 1:00 AM | Banyan Hill Publishing (Ad)Relay Therapeutics prices $275M public offering of common stock at $12/shareMay 21, 2026 | msn.comRelay Therapeutics: Encouraging Data, Competitive Risks (Downgrade)May 21, 2026 | seekingalpha.comRLAY stock declines pre-market after $175M offering — despite fresh bullish calls on Relay's zovegalisibMay 21, 2026 | msn.comRelay Therapeutics (NASDAQ:RLAY) CFO Sells $227,840.62 in StockMay 15, 2026 | insidertrades.comRelay Therapeutics (NASDAQ:RLAY) Insider Sells $11,136.87 in StockMay 1, 2026 | insidertrades.comSee More Headlines RLAY Stock Analysis - Frequently Asked Questions How have RLAY shares performed this year? Relay Therapeutics' stock was trading at $8.46 on January 1st, 2026. Since then, RLAY shares have increased by 59.9% and is now trading at $13.53. How were Relay Therapeutics' earnings last quarter? Relay Therapeutics, Inc. (NASDAQ:RLAY) announced its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.06. The firm had revenue of $3 million for the quarter, compared to analysts' expectations of $5.58 million. When did Relay Therapeutics IPO? Relay Therapeutics (RLAY) raised $370 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 20,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO. Who are Relay Therapeutics' major shareholders? Relay Therapeutics' top institutional investors include Dimensional Fund Advisors LP (1.54%), Bank of America Corp DE (1.01%), EcoR1 Capital LLC (0.99%) and Renaissance Technologies LLC (0.35%). Insiders that own company stock include Sanjiv Patel, Donald A Bergstrom, Brian Adams, Peter Rahmer and Thomas Catinazzo. View institutional ownership trends. How do I buy shares of Relay Therapeutics? Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Relay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Relay Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Novo Nordisk A/S (NVO), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings5/05/2026Today5/25/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 RLAY's financial health is in the Green zone, according to TradeSmith. RLAY has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLAY CIK1812364 Webwww.relaytx.com Phone617-370-8837FaxN/AEmployees330Year Founded2016Price Target and Rating Average Price Target for Relay Therapeutics$22.60 High Price Target$27.00 Low Price Target$18.00 Potential Upside/Downside+67.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$276.48 million Net MarginsN/A Pretax Margin-2,554.14% Return on Equity-43.94% Return on Assets-40.11% Debt Debt-to-Equity RatioN/A Current Ratio22.13 Quick Ratio22.13 Sales & Book Value Annual Sales$15.35 million Price / Sales168.87 Cash FlowN/A Price / Cash FlowN/A Book Value$3.35 per share Price / Book4.04Miscellaneous Outstanding Shares191,590,000Free Float181,930,000Market Cap$2.59 billion OptionableOptionable Beta1.74 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:RLAY) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
